Impact of angiogenic factors and maternal endothelial dysfunction on pregnancy outcome

Česká verze

Authors: M. Piklová ¹ ; A. Eschner ¹ ; J. Klicnarová ^1,2 ; M. Velemínský ^1,3
Authors place of work: Gynekologicko-porodnické oddělení, Nemocnice České Budějovice, a. s. ¹; Fakulta zemědělská a technologická, JU v Českých Budějovicích ²; Zdravotně sociální fakulta, JU v Českých Budějovicích ³
Published in the journal: Ceska Gynekol 2026; 91(2): 89-95
Category: Původní práce
doi: https://doi.org/10.48095/cccg202689

Summary

Aim: To analyze the relationship between the fibroblast growth factor soluble receptor 1 (sFlt-1/PlGF) ratio and adverse perinatal outcomes. Materials and methods: Patients admitted between 22+0 and 34+6 weeks of gestation from February 2024 to June 2025 were included. The sFlt-1/PlGF ratio was measured and its relationship to pregnancy outcome was evaluated. We assessed whether patients with increased sFlt-1/PlGF ratios developed conditions leading to preterm birth (spontaneous or iatrogenic). Results: A total of 78 patients were included, of whom 47 delivered before 37 weeks of gestation and 31 after 37 weeks. The sFlt-1/PlGF ratio appeared significant in relation to the risk of preterm birth. Almost all women with an sFlt-1/PlGF ratio above 100 delivered before 37 weeks. Based on the collected data, we developed a model to estimate the probability of delivery within 3 or 7 days. The model showed low sensitivity (0.32 and 0.53), but high specificity (0.91 in both cases). It accurately identified patients who would not deliver within 3 or 7 days. Conclusion: The sFlt-1/PlGF ratio is a useful tool in assessing the further course of pregnancy.

Keywords:

pre-eclampsia – angiogenic factors – placenta growth factor – fibroblast growth factor soluble receptor 1

Zdroje

1. Jung J, Romero R, Yeo L et al. The etiology of preeclampsia. Am J Obstet Gynecol 2022; 226 (2 Suppl): S844–S866. doi: 10.1016/j.ajog. 2021.11.1356.

2. Melchiorre K, Giorgione V, Thilaganathan B. The placenta and preeclampsia: villain or victim? Am J Obstet Gynecol 2022; 226 (2 Suppl): S954–S962. doi: 10.1016/j.ajog.2020.10.024.

3. Creswell L, O’Gorman N, Palrmer RK et al. Perspectives on the use of Placental Growth Factor (PlGF) in the prediction and diagnosis of pre-eclampsia: recent insights and future steps. Int J Womens Health 2023; 15 : 255–271. doi: 10.2147/IJWH.S368454.

4. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008; 11 (3): 215–221. doi: 10.1007/s10456-008-9114-4.

5. Rana S, Burke SD, Karumanchi SA. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol 2022; 226 (2 Suppl): S1019–S1034. doi: 10.1016/j.ajog.2020.10.022.

6. Romero R, Jung E, Chaiworapongsa T et al. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. Am J Obstet Gynecol 2022; 227 (4): 615.e1–615.e25. doi: 10.1016/j.ajog.2022.04.015.

7. Chaiworapongsa T, Romero R, Whitten AE et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 2016; 29 (8): 1214–1228. doi: 10.3109/14767058.2015.1048431.

8. Kusanovic JP, Romero R, Espinoza J et al. Twin--to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol 2008; 198 (4): 382.e1–382.e8. doi: 10.1016/j.ajog.2008.02.016.

9. Espinoza J, Romero R, Nien JK et al. A role of the anti-angiogenic factor sVEGFR-1 in the ’mirror syndrome’ (Ballantyne’s syndrome). J Matern Fetal Neonatal Med 2006; 19 (10): 607–613. doi: 10.1080/14767050600922677.

10. Romero R, Chaiworapongsa T, Erez O et al. An Imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med 2010; 23 (12): 1384–1399. doi: 10.3109/14767051003681121.

11. Foo FL, Mahendru AA, Masini G et al. Association between prepregnancy cardiovascular function and subsequent preeclampsia or fetal growth restriction. Hypertension 2018; 72 (2): 442–450. doi: 10.1161/HYPERTENSION AHA.118.11092.

12. Kampman MA, Bilardo CM, Mulder BJ et al. Maternal cardiac function, uteroplacental Doppler flow parameters and pregnancy outcome: a systematic review. Ultrasound Obstet Gynecol 2015; 46 (1): 21–28. doi: 10.1002/uog. 14697.

13. Chaiworapongsa T, Romero R, Savasan ZA et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factorsare of prognostic value in patients presenting to the obstetrical triagearea with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24 (10): 1187–1207. doi: 10.3109/14767 058.2011.589932.

14. Siepen C, Brennecke S. Does a sFlt-1/PlGF ratio result > 655 before 34 weeks’ gestation necessitate preterm delivery within 2 days? J Matern Fetal Neonatal Med 2024; 37 (1): 2371047. doi: 10.1080/14767058.2024.2371047.

15. Musilová I, Kremlacek J, Pavlíková L. sFlt-1/PlGF ratio is associated with delivery within 7 days in women with spontaneous preterm labor. Am J Obstet Gynecol 2024; 230 (4): e38–e42. doi: 10.1016/j.ajog.2023. 11.1233.